Sentences with phrase «human vaccine studies»

The assay will be validated against clinical outcomes in human vaccine studies (correlates of protection such as neutralising antibodies or vaccine - induced protection in human challenge models, or exploratory correlates such as multifunctional Th1 cells).

Thus, this study has implications for analysis of human vaccine studies, as in addition to searching for defined lineages it is worthwhile to perform functional analysis of monoclonal antibodies that may have found new structural solutions to high affinity binding which can not be discerned from DNA sequence alone.

Not exact matches

«Study offers new recommendations for TB vaccine testing in humans.»

Yet there is reason for optimism: the NIH has already developed a DNA vaccine against the West Nile virus that appeared promising in early human studies (although ultimately the NIH could not find a commercial partner to take that vaccine forward).

«We have followed a less potent neutralizing lineage in this particular individual before, but now we have found a far more potent antibody and have been able to study its development over six years,» said first author Mattia Bonsignori, M.D., of the Duke Human Vaccine Institute.

For their research, Pekosz and his team, using human nasal tract cells, studied the weakened strain of the flu virus that is used in the nasal spray vaccine and compared its behavior with that of the flu virus itself.

And scientists who conduct human challenge studies, which typically involve a few dozen participants, say they have critical benefits: In addition to saving time and money, they can reveal harm caused by a potential drug or vaccine before it enters large - scale human efficacy trials.

According to a study published in Human Vaccines & Immunotherapeutics, the Tdap vaccine is safe for both mothers and infants.

Last year the National Institutes of Health announced plans to put some 180 ex-Coulston chimps currently housed at the Alamogordo Primate Facility back in service, to rejoin the roughly 800 other chimps that serve as subjects for studies of human diseases, therapies and vaccines in the U.S., which is the only country apart from Gabon to maintain chimps for this purpose.

This study strengthens the argument for focusing on the malaria side of the parasite - human interaction in our search for new vaccine candidates.»

Profectus BioSciences in Tarrytown, New York, which is developing a similar vaccine, needs some $ 2 million to produce it under good manufacturing practice standards, a prerequisite for any human study.

Ding's next goal is to raise $ 5 million so he can spend about five years studying new vaccines for human pathogens such as dengue fever.

«Given the key similarities to human infections, a marmoset model of Zika may be useful for testing of new drug and vaccines,» said Texas Biomedical Research Institute virologist Jean Patterson, Ph.D. «Having an animal model of Zika infection to study may help us identify places where we might be able to block transmission.»

The multi-author study, by the Global Alliance for Rabies Control's Partners for Rabies Prevention Group, also shows that annual economic losses because of the disease are around 8.6 billion US dollars, mostly due to premature deaths, but also because of spending on human vaccines, lost income for victims of animal bites and other costs.

«There are several vaccines in human trials right now, but to date, none of them has been shown to protect during pregnancy,» said Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine at Washington University School of Medicine in St. Louis, and the study's co-senior author.

Guided by findings from human and monkey studies, researchers are working to improve upon the efficacy of the RV144 vaccine regimen.

The study, published Aug. 13, 2014, in the journal Cell Host & Microbe, builds on previous work from researchers at the Duke Human Vaccine Institute that outlined a perplexing quality about HIV: The antibodies that originally arise to fight the virus are ineffective.

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV - 16 / 18 AS04 - adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three - doses in the current schedule.

The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable.

Due to major advances in their immune potency DNA vaccines are being studied in human clinical trials for treating cancer and infectious diseases.

They have become a valuable resource for biologists, enabling momentous scientific breakthroughs including the development of the polio vaccine the Nobel Prize winning studies defining the role of telomerase in aging, and research on the causative role of human papillomavirus (HPV) in some types of cervical cancer.

The Pilot Bioproduction Facility headed by Dr. Kenneth H. Eckels, produced small batches of vaccine candidates that were used for the preclinical studies and is currently manufacturing a vaccine lot for use in initial human clinical studies.

A 2014 study used epidemiological data to show egg - based mutations are associated with low vaccine effectiveness in human populations.

The loss was bad for the vaccine: In a series of experiments Hensley and his colleagues showed antibodies from humans and ferrets (a good animal model for influenza A studies) that had been exposed to the egg - grown vaccine did not effectively kill the circulating sugar - adorned viruses.

When the team injected the vaccine into the skin of macaque monkeys, the reaction was similar to that in humans, but when injected into the bloodstream, the vaccine provided a strong and long - lasting CD8 + response in all three animals studied.

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

«You certainly can't do a $ 100 million study for every candidate vaccine that appears safe and immunogenic,» says Mark Mulligan, a molecular virologist who heads the vaccine center at Emory University in Atlanta and does human challenges with norovirus and tuberculosis.

Forty years ago Levine was one of a tiny cadre of researchers doing so - called human challenge studies — intentionally infecting people with V. cholerae and other pathogens to test drugs and vaccines.

Janssen, a division of Johnson & Johnson, described its plans to speed development of yet another Ebola vaccine strategy that has yet to enter human studies.

«In line with our company's commitment to address global health needs, we are committed to working with leading experts to develop a preventative HIV vaccine and our team is excited to advance this program into human clinical studies.»

«Taken together, these two studies suggest that the new scalable vaccine formulation is likely to prove as effective as the original formulation — which would make it the first protective TB vaccine in humans since BCG, which was introduced almost a century ago,» said Professor Ajit Lalvani, Director of the Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London and a member of the DAR - 901 development team.

«Investigational vaccine protects cattle from respiratory syncytial virus: Study provides model for developing an effective human RSV vaccine.»

The version of RSV that naturally infects cattle is closely related to human RSV, so the results suggest that a similar human RSV vaccine construct may provide protection in humans, according to the study authors.

The immunological benefits from the wild mice's gut bacteria may, in part, explain a persistent problem in disease research: Why disease experiments in lab mice, such as vaccine studies, turn out very differently in humans or other animals.

This new work suggests that anti-PD-1 antibodies might be equally effective in treating hepatitis C and other persistent human viral infections, says Christopher Walker, PhD, a senior author on the study and director of the Center for Vaccines and Immunity at Nationwide Children's.

The agency approved the vaccines with scant clinical data, relying instead on the same «strain change» rules that allow manufacturers to change the seasonal vaccine without conducting human studies.

After all the work of planning, funding and getting approval for a vaccine trial in humans, «you're talking at least about three years in a best - case scenario, if you have a very promising product,» said Matthew Laurens, an associate professor of pediatrics and medicine at the University of Maryland who was not associated with the study.

Phase II trial - an intermediate clinical trial for studying an experimental vaccine in humans.

Phase I trial - an early clinical trial designed to study an experimental vaccine in humans.

A retracted study linking the vaccine for human papillomavirus (HPV) to behavioral problems in mice has been republished by a different journal.

Recent studies have identified genetic variants that account for variability in human susceptibility and severity of infection and might be useful for vaccine and treatment development in malaria [80][84] and dengue [85], [86], for example.

What if he designed a similar vaccine for dogs, but with human DNA instead — would it be easier to get approval for this study?

Dr Peter Barlow says study represents a promising step forward in the rapid development of a safe and robust vaccine against Zika virus infection in humans.

Subsequent studies in animal models that are thought to mimic the human experience indicate RSV inactivated vaccine induces an increased CD4 + T lymphocyte response, primarily of Th2 cells and the occurrence of immune complex depositions in lung tissues [32], [42], [43].

First, this is a study in mice; DNA vaccines that work in mice have a sorry history of not working in humans.

Specifically, we will test samples from aged and, as a control, younger human subject before and after vaccination with the trivalent inactivated influenza vaccine (TIV) in an exploratory / confirmatory study design to assess age - related responsiveness to the vaccine.

The study relates to a particular type of vaccine (killed) against a particular virus, influenza, though the findings might hold true for other killed vaccines and for those vaccines consisting only of proteins produced by GM in bacteria, yeast or insect cells, against diseases such as hepatitis B (HBV) and human papilloma virus (HPV, the causative agent of cervical cancer).

Limitations of the present studies include their performance in mice only and uncertainty of the relevance of rodent models to SARS - CoV vaccines in humans.

Phase I studies in humans have been conducted with a whole virus vaccine and a DNA vaccine [29]--[30].

A pilot study of the vaccine in humans is scheduled to open soon at seven different sites.